On April 22, 2026 OREGA Biotech reported that interim results from the Phase 2 MATISSE trial evaluating IPH5201, a first-in-class CD39 blocking monoclonal antibody, in combination with durvalumab and platinum-based chemotherapy in patients with resectable early-stage non-small cell lung cancer (NSCLC) were presented on April 21st during a plenary session at AACR (Free AACR Whitepaper) 2026 by Professor Fabrice Barlesi (Gustave Roussy) and discussed by Professor Tina Cascone (MD Anderson).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation highlights:
Perioperative PD-(L)1 inhibitors combined with chemotherapy are now a standard of care in resectable early-stage NSCLC. However, further improvements in pathological complete response (pCR) and survival outcomes are still needed. IPH5201, a humanized anti-CD39 neutralizing antibody, is designed to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing immuno-activating ATP levels, as demonstrated in preclinical models.
In the ongoing Phase 2 MATISSE study:
40 patients with stage II–IIIA NSCLC were treated
The regimen demonstrated a safety profile comparable to preoperative platinium-based chemo+durvalumab
The observed pathological Complete Response (pCR) rates were:
5% in the overall population
7% in patients with PD-L1 ≥1%
50% in patients with PD-L1 ≥50%
These results compare favorably with historical data from the AEGEAN Phase 3 study.
Biomarker analyses confirmed CD39 target engagement and suggested a correlation between CD39+ tumor cell density and treatment response.
These findings support the continuation of the study, including ongoing recruitment of patients with PD-L1 ≥1%.
About IPH5201 antibody
IPH5201 is a first-in-class-humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ).
OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).
About NCT05742607 clinical trial
MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety.
(Press release, OREGA BIOTECH, APR 22, 2026, View Source [SID1234664684])